Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company developing azenosertib, an investigational oral WEE1 inhibitor, for patients with ovarian cancer and other tumor types. Its clinical development is focused on Cyclin E1-positive platinum-resistant ovarian cancer, with additional studies evaluating azenosertib in ovarian cancer combinations and other settings. The company’s programs include the DENALI and ASPENOVA trials of azenosertib as a monotherapy, and the MUIR trial evaluating it with bevacizumab as maintenance therapy. Zentalis also completed a monotherapy trial in uterine serous carcinoma and does not plan further development in that indication. Zentalis exclusively in-licenses or solely owns worldwide development and commercialization rights to azenosertib. It relies on third-party contract manufacturers to produce the drug candidate for preclinical and clinical testing and, if approved, commercial manufacture. Zentalis is headquartered in San Diego, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ZNTL in the last 30 days.
See all $ZNTL insider activity →Wedbush upgraded Zentalis Pharmaceuticals to Outperform from Neutral, raising its price target to $6 from $5, a 20% increase. The target implies a 244.8% upside from the Nov 9 close of $1.74.
Zentalis Pharmaceuticals (ZNTL) stock rose 5.2% in pre-market trading after beating Q3 2026 earnings estimates with a loss of $0.34 per share, better than the $0.58 estimate. The company reported $228.89 million in cash and expects to complete a clinical trial by November 2026, with a readout in early 2027. Analysts maintain a 'Buy' rating with a $7.33 price target.
Zentalis Pharmaceuticals, Inc. (ZNTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates • DENALI Part 1b survival data strengthen azenosertib's position as the potential first-in-class oral, non-chemotherapy, non-ADC therapy in pivotal development for Cyclin E1-po
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning ZNTL (Zentalis Pharmaceuticals, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 1 bearish.
Recent ZNTL coverage spans financial news, earnings and corporate actions.
Analyst upgrade and higher price target suggest upside potential.
Earnings beat and strong cash position support near‑term upside.
Clinical OS data and updated enrollment/readout timelines improve perceived probability of near-term regulatory and value inflection, while cash runway supports continued execution.
Positive interim survival data may lift Zentalis stock as the trial supports accelerated‑approval pathway.
Positive survival data in the biomarker‑positive subgroup may boost investor confidence in Zentalis' lead candidate.
AlphAI scores every news story that mentions ZNTL with an AI model for sentiment and relevance, and aggregates insider trades from Zentalis Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Wedbush upgraded Zentalis Pharmaceuticals to Outperform from Neutral, raising its price target to $6 from $5, a 20% increase. The target implies a 244.8% upside from the Nov 9 close of $1.74.
Zentalis Pharmaceuticals (ZNTL) stock rose 5.2% in pre-market trading after beating Q3 2026 earnings estimates with a loss of $0.34 per share, better than the $0.58 estimate. The company reported $228.89 million in cash and expects to complete a clinical trial by November 2026, with a readout in early 2027. Analysts maintain a 'Buy' rating with a $7.33 price target.
Zentalis Pharmaceuticals, Inc. (ZNTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates • DENALI Part 1b survival data strengthen azenosertib's position as the potential first-in-class oral, non-chemotherapy, non-ADC therapy in pivotal development for Cyclin E1-po
Zentalis Pharmaceuticals (ZNTL) presented interim data from the DENALI Part 1b study, showing median overall survival of 15.9 months for Cyclin E1-positive patients treated with azenosertib, compared to 7.5 months for Cyclin E1-negative patients. The study involved 102 heavily pretreated ovarian cancer patients. Zentalis is advancing azenosertib in ongoing Phase 3 trials for platinum-resistant ovarian cancer.
Zentalis Pharmaceuticals (ZNTL) reported interim data for its ovarian cancer drug azenosertib, showing median overall survival of 15.8 months in Cyclin E1-positive patients vs. 7.5 months in negative patients. The data will be presented at ESMO Congress 2026. The company is advancing Phase 3 trials for azenosertib in this biomarker-selected population.
Zentalis Pharmaceuticals (ZNTL) stock rose 4.4% in pre-market trading after Leerink Partners upgraded it to Outperform with an $8 price target, up from Market Perform and $4. The firm cited reduced risk for azenosertib, its lead oncology drug, ahead of key clinical data presentations at the ESMO Congress. The broader analyst consensus price target is $6.75. The stock trades within its 52-week range of $1.21 to $6.95.
WALTERS GROUP purchased 4,335,000 shares of Zentalis Pharmaceuticals, Inc. (ZNTL) at $3.50 ($15.17M total) on 2026-08-14. Filed jointly with WALTERS WILLIAM THURMAN (10% owner) and WALTERS SUSAN BERKLEY (10% owner).
Zentalis Pharmaceuticals shares fell about 15% in pre-open trading after the company announced and priced a large underwritten public offering. The deal issues 23 million shares at $3.50 each, with an option for up to 3.45 million more. Gross proceeds are about $80.5 million to fund trials and research for azenosertib.
Zentalis Pharmaceuticals (NASDAQ:ZNTL) shares fell about 6.5% in after-hours after it announced an underwritten public offering of common stock and pre-funded warrants. The company plans to use net proceeds plus existing cash for clinical trials, regulatory filings, manufacturing, and general corporate purposes. Joint bookrunners include TD Cowen, Guggenheim, and Oppenheimer.
Zentalis Pharmaceuticals, Inc. (ZNTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates • Following U.S. regulatory discussions, accelerated approval strategy remains intact, supported by DENALI Part 2 • Enrollment completed in Part 2a and 2b of the DENALI trial;
